Avantor Inc. Common Stock (AVTR)
Stock · NYSE · Industrials
$16.41as of 10/16/2026
Price chart
Active signals
AVTR Signal Track Record
How signals performed across all stocks →What AVTR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | +0.8% | 54% | July 28, 2026 |
| Bollinger Band BreakoutActive now | 23 | -0.9% | 48% | September 3, 2026 |
| Bollinger Band Breakdown | 22 | -1.8% | 32% | March 12, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +0.3% | 56% | July 2, 2026 |
| Any 20-session window (baseline) | -0.6% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AVTR
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized…
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Employees
- 13,500
- Website
- www.avantorsciences.com/
Fundamentals
- 1-day range
- $15.95$16.45
- Market cap
- $8.91B
- P/E (trailing)
- —
- P/E (forward)
- 18.71
- EPS (trailing)
- $-0.85
- Dividend yield
- —
- Beta
- 0.98
- Avg. volume
- 9.44M
How Avantor Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 11, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Avantor Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AVTRAvantor Inc. Common Stock$16.42▲ 2.05%Market cap $8.91BP/E —$7.27$16.38
- BIOBio-Rad Laboratories Inc. Class A Common Stock$353.7▼ 3.05%Market cap $9.16BP/E 43.88$236.73$396.23
- BRKRBruker Corporation Common Stock$54.8▼ 3.08%Market cap $7.95BP/E —$32.37$66.98
- TXG10x Genomics Inc. Class A Common Stock$69.86▼ 3.49%Market cap $5.79BP/E —$11.62$102.81
- RVTYRevvity Inc. Common Stock$152.64▼ 1.34%Market cap $12.74BP/E 72.12$81.22$166.25
- EYPTEyePoint Inc. Common Stock$2.99▼ 4.78%Market cap $1.08BP/E —$2.93$19.11
- CTKBCytek Biosciences Inc. Common Stock$5.25▼ 2.96%Market cap $537.23MP/E —$3.31$6.21
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AVTR Avantor Inc. Common Stock | $8.91B | — | $16.42 | ▲ 2.05% | $7.27$16.38 |
| BIO Bio-Rad Laboratories Inc. Class A Common Stock | $9.16B | 43.88 | $353.7 | ▼ 3.05% | $236.73$396.23 |
| BRKR Bruker Corporation Common Stock | $7.95B | — | $54.8 | ▼ 3.08% | $32.37$66.98 |
| TXG 10x Genomics Inc. Class A Common Stock | $5.79B | — | $69.86 | ▼ 3.49% | $11.62$102.81 |
| RVTY Revvity Inc. Common Stock | $12.74B | 72.12 | $152.64 | ▼ 1.34% | $81.22$166.25 |
| EYPT EyePoint Inc. Common Stock | $1.08B | — | $2.99 | ▼ 4.78% | $2.93$19.11 |
| CTKB Cytek Biosciences Inc. Common Stock | $537.23M | — | $5.25 | ▼ 2.96% | $3.31$6.21 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Morgan Stanley Maintains Equal-Weight on Avantor, Raises Price Target to $15benzinga · 10/13/2026
- 3 Cash-Producing Stocks We Find RiskyYahoo · 9/11/2026
Insider Activity
Insider Actions →- Eck Steven W · July 31, 2026 · Tax Withholding1.4K @ $13.78
- Sokenu Claudius · July 24, 2026 · Tax Withholding1.2K @ $11.44
- Walker Corey · June 21, 2026 · Tax Withholding3.0K @ $9.58
- Gregory T. Lucier · May 8, 2026 · Buy10.0K @ $8.32
- Murthy Mala · May 7, 2026 · Grant25.3K
- Dingemans Simon · May 7, 2026 · Grant25.3K
- Makin Louise · May 7, 2026 · Grant25.3K
- Michael Severino · May 7, 2026 · Grant25.3K
- Massaro Joseph R · May 7, 2026 · Grant25.3K
- Gregory T. Lucier · May 7, 2026 · Grant25.3K
- Gregory L. Summe · May 7, 2026 · Grant25.3K
- MEHRA SANJEEV K · May 7, 2026 · Grant25.3K
- Dingemans Simon · May 1, 2026 · Buy25.0K @ $8.14
- Brellier Ludovic · May 1, 2026 · Grant246.0K
- Brellier Ludovic · May 1, 2026 · Grant146.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 646.27M
- Total value held
- $4.89B
- Institutional holders
- 421
- Unknown119.65M
- Unknown65.70M
- Unknown30.61M
- Unknown24.22M
- Unknown22.59M
- Unknown22.36M
- Unknown20.72M
- Unknown19.78M
- Unknown16.89M
- Unknown14.79M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Avantor to Report Q3 2026 Earnings on October 28
Avantor has scheduled its third-quarter 2026 earnings release for Wednesday, October 28, 2026. Recent coverage notes that the company led peer groups in research tools and consumables during the second quarter. The stock is currently trading near the lower end of its 52-week range, with analysts maintaining a wide target price spread.
Avantor to Report Q3 2026 Earnings on October 28. Avantor has scheduled its third-quarter 2026 earnings release for Wednesday, October 28, 2026. Recent coverage notes that the company led peer groups in research tools and consumables during the second quarter. The stock is currently trading near the lower end of its 52-week range, with analysts maintaining a wide target price spread.